These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29435585)

  • 1. Legal Challenges to State Drug Pricing Laws.
    Lee TT; Kesselheim AS; Kapczynski A
    JAMA; 2018 Mar; 319(9):865-866. PubMed ID: 29435585
    [No Abstract]   [Full Text] [Related]  

  • 2. Limiting State Flexibility in Drug Pricing.
    Bagley N; Sachs RE
    N Engl J Med; 2018 Sep; 379(11):1002-1004. PubMed ID: 30207910
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 4. A New Way to Contain Unaffordable Medication Costs - Exercising the Government's Existing Rights.
    Engelberg AB; Avorn J; Kesselheim AS
    N Engl J Med; 2022 Mar; 386(12):1104-1106. PubMed ID: 35139270
    [No Abstract]   [Full Text] [Related]  

  • 5. States on the Front Line: Addressing America's Drug Pricing Problem.
    Riley T; Lanford S
    J Leg Med; 2019; 39(2):81-93. PubMed ID: 31503529
    [No Abstract]   [Full Text] [Related]  

  • 6. Will Courts Allow States to Regulate Drug Prices?
    Robertson C
    N Engl J Med; 2018 Sep; 379(11):1000-1002. PubMed ID: 30088965
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceuticals and medical devices: cost savings.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
    [No Abstract]   [Full Text] [Related]  

  • 9. The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs.
    Gudiksen KL; King JS
    J Leg Med; 2019; 39(2):95-120. PubMed ID: 31503534
    [No Abstract]   [Full Text] [Related]  

  • 10. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 11. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
    Jones TM
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-58. PubMed ID: 20213918
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceutical costs. An overview and analysis of legal and policy responses by the states.
    Latham SR
    J Leg Med; 2003 Jun; 24(2):141-73. PubMed ID: 12775406
    [No Abstract]   [Full Text] [Related]  

  • 14. Zuma pacifies pharmaceutical manufacturers.
    van der Linde I
    S Afr Med J; 1999 Jan; 89(1):26. PubMed ID: 10070401
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Health Policy Tracking Service, A Service of Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-21. PubMed ID: 21374837
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-18. PubMed ID: 20213921
    [No Abstract]   [Full Text] [Related]  

  • 17. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM; Curfman GD
    N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
    [No Abstract]   [Full Text] [Related]  

  • 18. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS
    Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract]   [Full Text] [Related]  

  • 19. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
    Jones TM
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-32. PubMed ID: 18345554
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.